UK-based biotechnology company ExpressionEdits has secured $13m in a seed funding round to advance the development of protein based therapies leveraging artificial intelligence (AI)-driven intronization technology.
Lucy Therapeutics (LucyTx) has secured $12.5m in additional financing round to advance the development of new treatments for Alzheimer's and Parkinson's diseases.
Venture-backed biotechnology company RevolKa has entered into a master service agreement with Daiichi Sankyo for functional proteins.
Radar Therapeutics has successfully completed an oversubscribed seed funding round, raising $13.4m for developing smart programmable medicines.
Teva and Alvotech have announced the US launch of SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to the reference product Humira to treat arthritis.
ERS Genomics and IRBM have entered into a non-exclusive license agreement, granting the latter access to ERS Genomics' extensive clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 patent portfolio.
FogPharma has partnered with ARTBIO to co-develop Helicon-enabled alpha radioligand therapies (HEARTs), a new class of treatments aimed at improving outcomes for cancer patients.
PharmaLogic, a contract development and manufacturing organization (CDMO) and provider of radiopharmacy solutions, has announced the launch of its new radiopharmaceutical manufacturing and research facility at the Bronx in New York city, US.
Aardvark Therapeutics has secured $85m in an oversubscribed Series C financing round, with Decheng Capital spearheading the investment, to complete studies of ARD-101.
Data-driven biotechnology company OverT Bio has secured $16m in a seed funding round to expand its discovery platforms aimed at developing cellular therapies for solid tumours.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.